Allergan’s BOTOX (onabotulinumtoxinA) Receives the US FDA’s Approval for Pediatric Patients with Lower Limb Spasticity Excluding Spasticity Caused by Cerebral Palsy

 Allergan’s BOTOX (onabotulinumtoxinA) Receives the US FDA’s Approval for Pediatric Patients with Lower Limb Spasticity Excluding Spasticity Caused by Cerebral Palsy

Allergan; BOTOX; onabotulinumtoxinA; Receives; US; FDA; Approval; Pediatric Patients; Lower Limb Spasticity; Spasticity Caused by Cerebral Palsy

Shots:

  • The FDA’s approval is based on P-III study assessing the BOTOX in 300+ pediatric patients aged 2-17yrs. being treated for lower limb spasticity. The study included patients with cerebral palsy, but the approved indication excludes lower limb spasticity caused by cerebral palsy due to marketing exclusivity by another company
  •  The approval marks the 11th BOTOX therapeutic indication and comes 30yrs. after the first indications were approved and recently has been approved for pediatric upper limb spasticity in H1’2019
  • BOTOX is a neurotoxin therapy injected in the muscles to treat increased muscle stiffness & eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm)

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Business Insider

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post